CFO
TNYA icon

Callan Family Office’s Tenaya Therapeutics TNYA Stock Holding History

Callan Family Office’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37K Hold
50,061
– – ﹤0.01% 1205
2026
Q1 		$34.7K Hold
50,061
– – ﹤0.01% 1118
2025
Q4 		$35.6K Buy
50,061
+13,792
+38% +$18.8K ﹤0.01% 1099
2025
Q3 		$58.8K Hold
36,269
– – ﹤0.01% 833
2025
Q2 		$22.2K Sell
36,269
-51,908
-59% -$26.4K ﹤0.01% 913
2025
Q1 		$50.3K Buy
+88,177
New +$87K ﹤0.01% 540

Other funds holding TNYA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.77B AUM 65.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Callan Family Office's TNYA Position: Q2 2026 in Review

Callan Family Office held its Tenaya Therapeutics (TNYA) position steady in Q2 2026 at 50,061 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #1205.

Callan Family Office first reported a position in TNYA in Q1 2025 and has held it in 6 quarters since. The position peaked at $58.8K in Q3 2025. 101 funds tracked by Wall St. Rank hold TNYA as of Q2 2026.

  • Callan Family Office held 50,061 shares of Tenaya Therapeutics worth $37K as of Q2 2026.
  • Callan Family Office left its Tenaya Therapeutics share count unchanged in Q2 2026.
  • Tenaya Therapeutics made up ﹤0.01% of Callan Family Office's portfolio in Q2 2026, its #1205 holding.
  • Callan Family Office first reported a position in Tenaya Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Callan Family Office's Tenaya Therapeutics position peaked at $58.8K in Q3 2025.
  • 101 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.